NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
Clinical Trials
73 trialsNCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT06005974 2026-02-23
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
Phase 2 Terminated
NCT00923806 2026-01-23
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT04799054 2026-01-20
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
NCT06162351 2026-01-02
TOPOLOGY
Institut Curie
Phase 2 Terminated
NCT06337630 2026-01-02
POP-ART
Institut Curie
Phase 1 Terminated
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT04701281 2025-09-18
SYS-CAPLIOX
AllVascular
Phase 1/2 Terminated
NCT06175221 2025-09-15
Autologous TLPO Vaccine Basket
Elios Therapeutics, LLC
Phase 2 Terminated
NCT03871348 2025-09-10
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Terminated
NCT05490043 2025-08-29
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene Corporation
Phase 1 Terminated
NCT06877533 2025-08-12
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Terminated
NCT05471271 2025-05-31
IL-2 PET Imaging in Advanced Solid Tumours
University Medical Center Groningen
Phase NA Terminated
NCT04418661 2025-05-29
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT05840510 2025-04-25
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT05904236 2025-04-08
ICVB-1042
IconOVir Bio
Phase 1 Terminated
NCT01529593 2025-03-24
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05126433 2025-02-28
JAZZ EMERGE201
Jazz Pharmaceuticals
Phase 2 Terminated
NCT04812535 2025-02-11
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
InflaRx GmbH
Phase 2 Terminated
NCT05781360 2024-12-20
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT05198349 2024-11-25
First in Human Study of M1069 in Advanced Solid Tumors
EMD Serono
Phase 1 Terminated
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT04534283 2024-08-07
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Indiana University
Phase 2 Terminated
NCT05631327 2024-05-28
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
Jazz Pharmaceuticals
Phase 1 Terminated
NCT04618393 2024-05-21
A Study of EMB-02 in Participants With Advanced Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 1/2 Terminated
NCT04250597 2024-05-06
Study of GNX102 in Patients With Advanced Solid Tumors
GlycoNex, Inc.
Phase 1 Terminated
NCT04738292 2024-05-03
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
University of Wisconsin, Madison
Phase 2 Terminated
NCT05071183 2024-04-02
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT04729725 2023-08-14
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02478320 2023-07-17
Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03995927 2023-06-29
PROCC
Wake Forest University Health Sciences
Terminated
NCT04194528 2023-06-27
S1916 Digital Medicine Program for Pain Control in Cancer Patients
SWOG Cancer Research Network
Phase NA Terminated
NCT04763135 2023-06-08
MIR-P
Hospices Civils de Lyon
Phase 3 Terminated
NCT00886782 2023-04-28
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT02452268 2023-03-03
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Novartis
Phase 1 Terminated
NCT02773966 2022-07-22
Kypho-IORT vs. EBRT in Spinal Metastases
Universitätsmedizin Mannheim
Phase 3 Terminated
NCT02801097 2022-05-17
PAYLOAD
EpicentRx, Inc.
Phase 1 Terminated
NCT04003623 2022-05-10
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Incyte Corporation
Phase 2 Terminated
NCT02571530 2021-11-03
Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
Northwell Health
Phase 1 Terminated
NCT01240642 2020-12-09
An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404
Novartis
Phase 1 Terminated
NCT01278758 2020-12-09
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
Novartis
Phase 1 Terminated
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT03119428 2020-08-11
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mereo BioPharma
Phase 1 Terminated
NCT03295942 2020-08-11
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
Mereo BioPharma
Phase 1 Terminated
NCT02353000 2020-06-01
WBRTvsSRS
Maastricht Radiation Oncology
Phase NA Terminated
NCT02265510 2020-04-17
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT00028652 2019-12-13
Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases
University of Wisconsin, Madison
Phase 1 Terminated
NCT03494231 2019-07-30
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
Henlix, Inc
Phase 1 Terminated
NCT02548390 2019-04-25
Study of Intravenous RXDX-107 in Patients With Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated